Wall Street brokerages expect Diplomat Pharmacy, Inc. (NYSE:DPLO) to post $1.14 billion in sales for the current fiscal quarter, Zacks reports. Six analysts have made estimates for Diplomat Pharmacy’s earnings, with estimates ranging from $1.12 billion to $1.16 billion. Diplomat Pharmacy reported sales of $1.18 billion in the same quarter last year, which indicates a negative year-over-year growth rate of 3.4%. The company is scheduled to announce its next earnings report after the market closes on Monday, November 6th.

According to Zacks, analysts expect that Diplomat Pharmacy will report full-year sales of $1.14 billion for the current year, with estimates ranging from $4.46 billion to $4.54 billion. For the next financial year, analysts forecast that the business will post sales of $5.11 billion per share, with estimates ranging from $4.98 billion to $5.28 billion. Zacks Investment Research’s sales averages are an average based on a survey of analysts that that provide coverage for Diplomat Pharmacy.

Diplomat Pharmacy (NYSE:DPLO) last issued its earnings results on Monday, August 7th. The company reported $0.25 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.15 by $0.10. Diplomat Pharmacy had a return on equity of 7.97% and a net margin of 0.27%. The business had revenue of $1.13 billion during the quarter, compared to analysts’ expectations of $1.14 billion. During the same quarter in the previous year, the business earned $0.23 EPS. The company’s revenue for the quarter was up 3.5% on a year-over-year basis.

DPLO has been the subject of a number of recent research reports. Robert W. Baird raised Diplomat Pharmacy to a “positive” rating and raised their price target for the stock from $20.00 to $24.00 in a research note on Monday, September 18th. Zacks Investment Research downgraded Diplomat Pharmacy from a “hold” rating to a “sell” rating in a research note on Monday, July 17th. Needham & Company LLC initiated coverage on Diplomat Pharmacy in a research note on Friday, July 21st. They set a “buy” rating and a $19.75 price target for the company. Finally, BidaskClub raised Diplomat Pharmacy from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 5th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. Diplomat Pharmacy currently has an average rating of “Hold” and a consensus target price of $19.69.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Louisiana State Employees Retirement System increased its holdings in shares of Diplomat Pharmacy by 0.6% during the 2nd quarter. Louisiana State Employees Retirement System now owns 17,800 shares of the company’s stock valued at $263,000 after acquiring an additional 100 shares during the last quarter. Capstone Asset Management Co. increased its holdings in shares of Diplomat Pharmacy by 0.5% during the 2nd quarter. Capstone Asset Management Co. now owns 24,430 shares of the company’s stock valued at $362,000 after acquiring an additional 120 shares during the last quarter. Arizona State Retirement System increased its holdings in shares of Diplomat Pharmacy by 0.9% during the 2nd quarter. Arizona State Retirement System now owns 22,800 shares of the company’s stock valued at $337,000 after acquiring an additional 200 shares during the last quarter. Bank of Montreal Can increased its holdings in shares of Diplomat Pharmacy by 3.0% during the 2nd quarter. Bank of Montreal Can now owns 11,600 shares of the company’s stock valued at $172,000 after acquiring an additional 340 shares during the last quarter. Finally, Texas Permanent School Fund increased its holdings in shares of Diplomat Pharmacy by 1.5% during the 2nd quarter. Texas Permanent School Fund now owns 31,890 shares of the company’s stock valued at $472,000 after acquiring an additional 470 shares during the last quarter. 69.90% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This news story was originally published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/10/19/zacks-analysts-expect-diplomat-pharmacy-inc-dplo-will-post-quarterly-sales-of-1-14-billion.html.

Shares of Diplomat Pharmacy (DPLO) opened at 20.78 on Thursday. Diplomat Pharmacy has a one year low of $12.25 and a one year high of $29.36. The stock’s 50 day moving average price is $19.82 and its 200-day moving average price is $17.17. The stock has a market cap of $1.41 billion, a PE ratio of 113.55 and a beta of 0.74.

Diplomat Pharmacy Company Profile

Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.

Get a free copy of the Zacks research report on Diplomat Pharmacy (DPLO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Diplomat Pharmacy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy Inc. and related companies with MarketBeat.com's FREE daily email newsletter.